Rivaroxaban Use for Central Nervous System Thrombotic Events in Neonates: A Case Series

Background: Central nervous system (CNS) thrombotic events in neonates are a rare but severe condition. Evidence on the use of direct oral anticoagulants in this population is extremely limited, and rivaroxaban use remains off label. Objectives: To describe the safety and effectiveness outcomes of rivaroxaban use in neonates with CNS thrombotic events. Methods: We conducted a retrospective case series including all neonates treated with rivaroxaban for CNS thrombotic events in two tertiary neonatal intensive care units between January and December 2025. Clinical, laboratory, thrombophilia screening, treatment, imaging, and outcome data were retrospectively collected. Rivaroxaban was administered as an oral suspension (Xarelto®, 1 mg/mL) following initial parenteral anticoagulation. We reported effectiveness and safety outcomes. Results: Six term neonates were included. Rivaroxaban was initiated between 13 and 31 days of life using weight-based dosing. Maternal or perinatal risk factors were identified in five cases, while thrombophilia screening revealed heterogeneous and isolated abnormalities without a consistent inherited prothrombotic profile. Among six neonates with adequate imaging follow-up, complete thrombus resolution was documented in three cases and partial resolution in two cases, with no thrombus progression or recurrence. One neonate showed imaging evolution related to the initial cerebral injury without documented thrombus resolution. One minor bleeding event occurred (a transient conjunctival bleeding), without need for treatment modification. No major bleeding events, treatment interruptions, or deaths were observed. Conclusions: In this neonatal case series, off-label rivaroxaban use for CNS thrombosis was feasible and generally well tolerated, with favorable effectiveness outcomes in patients on available neuroimaging follow-up. Larger prospective studies are needed to define safety, effectiveness, and optimal dosing in neonates.

Authors

Institutions

Publication Details

Journal
Children
Published
2026-11-19
DOI
https://doi.org/10.3390/children13111611
Primary Topic
Blood Coagulation and Thrombosis Mechanisms
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Rivaroxaban Use for Central Nervous System Thrombotic Events in Neonates: A Case Series

Francesca Campi, Chiara Maddaloni, Sara Ronci, Annabella Braguglia et al.
Children
Blood Coagulation and Thrombosis Mechanisms
article

Rivaroxaban Use for Central Nervous System Thrombotic Events in Neonates: A Case Series

Francesca Campi, Chiara Maddaloni, Sara Ronci, Annabella Braguglia, Andrea Dotta, Domenico Umberto De Rose, Roberta Arena, Francesca Gallini, Matteo Luciani, Valerio Romano, Daniela Longo
article en

Abstract

Background: Central nervous system (CNS) thrombotic events in neonates are a rare but severe condition. Evidence on the use of direct oral anticoagulants in this population is extremely limited, and rivaroxaban use remains off label. Objectives: To describe the safety and effectiveness outcomes of rivaroxaban use in neonates with CNS thrombotic events. Methods: We conducted a retrospective case series including all neonates treated with rivaroxaban for CNS thrombotic events in two tertiary neonatal intensive care units between January and December 2025. Clinical, laboratory, thrombophilia screening, treatment, imaging, and outcome data were retrospectively collected. Rivaroxaban was administered as an oral suspension (Xarelto®, 1 mg/mL) following initial parenteral anticoagulation. We reported effectiveness and safety outcomes. Results: Six term neonates were included. Rivaroxaban was initiated between 13 and 31 days of life using weight-based dosing. Maternal or perinatal risk factors were identified in five cases, while thrombophilia screening revealed heterogeneous and isolated abnormalities without a consistent inherited prothrombotic profile. Among six neonates with adequate imaging follow-up, complete thrombus resolution was documented in three cases and partial resolution in two cases, with no thrombus progression or recurrence. One neonate showed imaging evolution related to the initial cerebral injury without documented thrombus resolution. One minor bleeding event occurred (a transient conjunctival bleeding), without need for treatment modification. No major bleeding events, treatment interruptions, or deaths were observed. Conclusions: In this neonatal case series, off-label rivaroxaban use for CNS thrombosis was feasible and generally well tolerated, with favorable effectiveness outcomes in patients on available neuroimaging follow-up. Larger prospective studies are needed to define safety, effectiveness, and optimal dosing in neonates.

ChildrenVol. 13(11)
Bambino Gesù Children's Hospital (IT), Fondazione Bambino Gesù (IT)
Blood Coagulation and Thrombosis Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon